Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, describes the advantages of natural killer (NK) cell therapy in treating lymphomas and leukemias. NK cells innately target tumors and therefore have a different safety profile compared to chimeric antigen receptor (CAR) T-cell therapy, where NK cell therapy is less likely to result in immune effector cell-associated neurotoxicity syndrome (ICANS) or cytokine release syndrome (CRS). NK cells additionally can contain a CAR, as in the case of FT596, and due to their off-the-shelf nature, can be administered in a short space of time. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.